{"name":"Jiangsu Hengrui Pharmaceutical Co., Ltd.","slug":"jiangsu-hengrui-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"jiangsuhengrui.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Fentanyl and Propofol","genericName":"Fentanyl and Propofol","slug":"fentanyl-and-propofol","indication":"Induction and maintenance of general anesthesia","status":"marketed"},{"name":"Butorphanol and Propofol","genericName":"Butorphanol and Propofol","slug":"butorphanol-and-propofol","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Fentanyl and Propofol","genericName":"Fentanyl and Propofol","slug":"fentanyl-and-propofol","phase":"marketed","mechanism":"Fentanyl is an opioid agonist that binds mu opioid receptors to provide analgesia, while propofol is a sedative-hypnotic that enhances GABA inhibitory neurotransmission to induce unconsciousness.","indications":["Induction and maintenance of general anesthesia","Sedation in intensive care units","Procedural sedation"],"catalyst":""},{"name":"Butorphanol and Propofol","genericName":"Butorphanol and Propofol","slug":"butorphanol-and-propofol","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOaTBneEVHeFVJUUdFSnF0Vk9JTFgwVkJtbF9LdGw2ZEFQamY2dkNqbG1iSTNQbUNtenZocENud0RYemp3Nlh4UmNDckZESFh6dnNiQkFTV1ctbkZYMmJsNVY5SGhjVnV3RTh6SnRBeDN2U0xCcXgwVE5VSG9kcmFGR050WQ?oc=5","date":"2026-04-02","type":"pipeline","source":"BioWorld News","summary":"Hengrui discovers new Nav1.8 blockers - BioWorld News","headline":"Hengrui discovers new Nav1.8 blockers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOSHdYOGFWb1pZV055LWRnMENGelptX3FFaDhyY3k4ZXJDc2J3eWJjMWNfQmRHZUo2djJFYXdkb3E0ZllwdERqaWx4U1VwX202Sk5rRFZmSXN5UzIwejhHalEtUW0wUTlhYnV2eWxZd0lodDdnaTNpbGVPMWNaTEI2bjFIaGdBZjJ0aFpBVXNVUmdiVmxDT3V2MmhIbUlQUXl4REdpNlFhMWVKdUUwMVMxV3JFc2w5YUFQTE1fdnBrTXM1Tk4yX0VzN0JYQ0dxU0lUa0R0bFlWdFBEUQ?oc=5","date":"2026-03-26","type":"pipeline","source":"Moomoo","summary":"Press Release: Hengrui Pharma Announces Strong 2025 Annual Results - Moomoo","headline":"Press Release: Hengrui Pharma Announces Strong 2025 Annual Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPTks2Unp4bGtMeGRreHpILVdGZEEwYkR5VW94SE5nQWJLcE9qTmhIYmtrQ3ZoWjVCXzkzeHVSTHFqN05PTHhzdDdwa2pxQmllTDBzMWIzdmcyNEk3WmFFTzBveFdHX0Jzb09XcEQ2N1YtZHFiaGU1d0xCY2pKdFRFaGx1bmx1UkJsZkx1MVR1Ri1DMWR6NkY2TGV1N2dWbXZuZGFVSks4dXp6OWdmSGctcHVVQ2hENWFkZktGdDZn?oc=5","date":"2026-03-25","type":"pipeline","source":"TipRanks","summary":"Jiangsu Hengrui Pharmaceuticals Publishes 2025 Audited Annual Results - TipRanks","headline":"Jiangsu Hengrui Pharmaceuticals Publishes 2025 Audited Annual Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOMjBkbF80eFJWRDJhbFBYX25nTmp5ektGWXFldllYWGRqREVKWnJGVDJWMUR1TkQ1V2xOT3RmVHpDUXhRbEhlSS1ZR243bm9aVFRETk1reEY3NmNXYjVHS0RWcmVxYTJaN01wQ2hGNDBYNWIzWUxnQ3EyWGVtS3V2TUl0ZmhXVk85ZFpRRFJGZThYRDhOdnk1QkRkdDVpaG5FU3pVVXppeHVEUXVobWhNZGxYWUYyclVGWnJEUk5uVkpqeDQ?oc=5","date":"2026-03-25","type":"pipeline","source":"FinancialContent","summary":"Hengrui Pharma Announces Strong 2025 Annual Results - FinancialContent","headline":"Hengrui Pharma Announces Strong 2025 Annual Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxOdWJEZHA1ZVp5SGJ6SmNoNmJZcndMbGhFckVJM2hJZUpxSjZoU1Y0QXViQWZNM3ZRY0t1UzlSVTJFejZLWHFFNm5JRHBZSGR0NWhUbWlwWF9hN0VrOEcwSmJkX0xlRGVEUVROTEVUckR3SVFtYUVGa2tKb3dodzZBeGpnRm90cGZ3MEVTaGFyNHQ2aUNENzVBZGxGR2MxT2lFU2RGY3VYZmhtWTNfdHcyWHh2RWJGeEMway1jaVBhSU9vMDRDMHRQV3Bzb3FLZWlTVHJsYm9SLXF3elhEek1uUXFZNA?oc=5","date":"2026-03-24","type":"pipeline","source":"marketscreener.com","summary":"Shanghai Ruihongdi Pharmaceutical Co., Ltd. announced that it expects to receive CNY 750 million in funding from Shanghai Shengdi Private Equity Fund Management Co., Ltd., Shenzhen Yingtai Asset Manag","headline":"Shanghai Ruihongdi Pharmaceutical Co., Ltd. announced that it expects to receive CNY 750 million in funding from Shangha","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQSDJIQUtuTU1OZ2gxMXVLQnNwd2dWalU0YWVtQThSa3IzeWRES0x6SEtCYW1BQlo5cXRvY1ZKaXMxaExHWFhqX3N3SVlTV2F4Z1RiLWZtVjI5ejVwSmRWVktacHZIbVh4UVRHZFBpSkxTdmNVbGFPZ3puQjBjOUQyQnRQeHZBTW1XSXI4?oc=5","date":"2026-03-02","type":"pipeline","source":"Pharma Voice","summary":"Big Pharma’s next entrant could come from China - Pharma Voice","headline":"Big Pharma’s next entrant could come from China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPajRXUkxjMGZiSXFMeU9TUjVTZU9Ldk45eEdrMUxmZDlZZjZoRTRMb296U1ZGdTRJODlXUEZUVTY3a0RPdzFCVTlfZERaUG9nRVREd3ppUGU1WHpGS0QzRkE2OHA4RDdhaDdfUlpGbWI3bWFLUW0wRjNaYy16QzN6bDUxeXJBazR1WXZ5bm8yZjVMaklBVm1KT0FVd2l4SXpBd1E?oc=5","date":"2025-12-14","type":"pipeline","source":"The Wire China","summary":"Company In the News — Hengrui Pharma - The Wire China","headline":"Company In the News — Hengrui Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQbTc3eTdzcUk4cWpqTkd3ZjZjR21vR3ZXYmwwMm5qUl8yMnBFT1REMlVHZ0YtYWMyWjE5elZYTjNzNmVXQUtQdUJfOFktSGJrUk1xdDhrZk92MXc5QW56YWxaWDZNYzlWaFVVNGNjMmVWMVpwRE5yd282eUVmcEJ3c25BTXFhSktjYVVMRGRRTUtzd2dOd3pBNV8tcUdHb2JxWHZjczZsSzFJZTZG?oc=5","date":"2025-11-29","type":"earnings","source":"Statista","summary":"Annual revenue of Jiangsu Hengrui Pharmaceuticals Co., Ltd. from 2015 to 2024 - Statista","headline":"Annual revenue of Jiangsu Hengrui Pharmaceuticals Co., Ltd. from 2015 to 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9hYTFTcmJWblhkS05GTXJEaHFQMUlrUDNXYTRyWHREVVBTUEJLLUZXSF8tNUJ3cGNLNnFyc3kwV2hxZkFZMExiSHV4SUIyOThyYVR4S0dpdjdkUzZHT3NnNVkyRUlLTy1KOWdfRnRrVDRhRWZyektHQTRyel9EZw?oc=5","date":"2025-11-20","type":"pipeline","source":"pharmaphorum","summary":"The importance of globalisation for patient access - pharmaphorum","headline":"The importance of globalisation for patient access","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQUGpsODM0QnE0alFCOUc1YVp5dm9pT1ZmN1ZFcGJWeFAwSzRTaGtJODlVaEJJZlVFMGpQVWtpYnZEMFhoQTZkNDJHRDZ5VVhUcHNZLXJxOGNMMjNobTRKUXpXdlBwV01MY1RaVE5abEFBbnB1WjRRbG1WZldmOUxxT19UNWNjdEdUTFBUOEtjUF82bW9nR29MNG5CVm9Ya1pFcEVfUF93ZzhXQTNrZTR4dHVKYlhKRXEycEtRaW1QS2JBWkcySC1BWVBpMi0zR0pXLW9uSFFn?oc=5","date":"2025-07-28","type":"deal","source":"Reuters","summary":"GSK, China's Jiangsu Hengrui strike $500 million drug-development deal - Reuters","headline":"GSK, China's Jiangsu Hengrui strike $500 million drug-development deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPandkMnQwNEl6TFNNWFJPMFF6Z3c4MlFzbEZKUnQwbnpUYm91eFQtSGVYMDN1MS1xMXJLdGpWckIweGM1bEl0S0ZQRXU4UkY2VTFrWERkNjBYN1VrcjkzVGMxbHBmWV9QZ2NOZW5pUE42LVlRX0Jpa0xrT2FCLWllU1BCVV8wSmd6ZzdnZmJuNlU?oc=5","date":"2025-07-28","type":"pipeline","source":"GSK","summary":"GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology - GSK","headline":"GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflam","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQR01VWktIR2toXzg2aF85S1VEVk5xOXVxM3k4VEVka01iaWRQVzZOSHF4aFVfVmdYcnpKMmVuY05rS3BkWUJrb05ORXM4SGpJeEVxMkt0S0h4S0VSTFkyMTYwVkxCVmNGSG5xd2NDLXdMZHZaNkpxT2pidHNiUkNkb25lamd0dGlELV9xTVo0RkRDUVZMWldQQ2JzWWkxSzdLOVRRMEJLMWpjYVhKb05QdzJ3UnA?oc=5","date":"2025-05-23","type":"pipeline","source":"Cleary Gottlieb","summary":"Jiangsu Hengrui Pharmaceuticals in HK$9.9 Billion IPO - Cleary Gottlieb","headline":"Jiangsu Hengrui Pharmaceuticals in HK$9.9 Billion IPO","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}